Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial isn't testing a treatment directly in patients — it's using blood samples from critically ill ARDS patients to study a new agent called PIP-2 in a lab setting. Can you help me understand what that would actually mean for me, and whether participating would change any part of my current care?
2. 2Since the study is measuring reactive oxygen species and immune cell activation in lab models, what would be involved on my end — how often would blood samples be taken, and would that add any burden or risk given how sick I already am?
3. 3This trial has no assigned phase, which suggests it's very early-stage research focused on understanding the science rather than proving a treatment works yet. Given that, would participating in this study have any direct benefit for me, or would it mainly help future patients?
4. 4Are there standard treatments for ARDS that my care team would recommend focusing on first, rather than or alongside participating in this observational and lab-based study?
5. 5If my blood samples are used to develop in vitro models and test PIP-2, what happens to that data and those samples long-term — and would I have any way to learn what the researchers find out?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.